Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation

19 Dec 2022

Abstract excerpt

For most patients with acute myeloid leukemia (AML), an allogeneic hematopoietic stem cell transplantation (HSCT) offers the highest chance of cure. Recently, the European LeukemiaNet (ELN) published updated recommendations on the diagnosis and risk classification in AML based on genetic factors at diagnosis as well as a dynamic adjustment (reclassification) according to the measurable residual disease (MRD)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36529759
DOI: 10.1038/s41408-022-00764-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantationPMID 36529759Read ↗

Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group.Semantic proximity Read ↗

Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study.Semantic proximity Read ↗

Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.Semantic proximity Read ↗

Comparison of disease and risk classifications of AML before and after incorporation of NGS analysis of bone marrow samples.Semantic proximity Read ↗

Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.Semantic proximity Read ↗

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group.Semantic proximity Read ↗

Predictive significance of the European LeukemiaNet classification of genetic aberrations in patients with acute myeloid leukaemia undergoing allogeneic stem cell transplantation.Semantic proximity Read ↗

Unified classification and risk-stratification in Acute Myeloid LeukemiaSemantic proximity Read ↗

Assessment of 2022 European LeukemiaNet risk classification system in real-world cohort from China.Semantic proximity Read ↗

Clinical features and prognostic nomogram for therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantationSemantic proximity Read ↗

Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.Semantic proximity Read ↗

Allogeneic stem cell transplantation for myelofibrosis in the modern era: single- center outcomes with DIPSS risk stratificationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.